Upon joining the study, eligibility is confirmed based on specific criteria. Participants must be at least 18 years old and have undergone isolated coronary artery bypass grafting (CABG) for coronary artery disease.

The condition of interest is new-onset post-operative atrial fibrillation (POAF) that lasts more than 60 minutes or occurs more than once within 7 days after the CABG surgery.

Participants receive oral anticoagulant medications to prevent blood clots. These medications include clopidogrel, apixaban, ticagrelor, rivaroxaban, dabigatran etexilate, edoxaban, and acetylsalicylic acid.

The medications are administered in the form of film-coated tablets or hard capsules, taken orally. Dosages vary, such as Clopidogrel 75 mg, Eliquis 2.5 mg, Brilique 60 mg, Xarelto 10 mg, Pradaxa 75 mg, Lixiana 15 mg, and Aspirin 500 mg.

Participants are monitored for the effectiveness of the treatment in preventing thromboembolic events, such as stroke or heart attack, and for safety concerning major bleeding.

The primary effectiveness endpoint includes a composite of death, ischemic stroke, transient ischemic attack, myocardial infarction, and thromboembolism.

The primary safety endpoint focuses on significant bleeding events.

At 90 and 180 days after randomization, the incidence of primary effectiveness and safety endpoints is evaluated.

Secondary endpoints include cardiovascular and non-cardiovascular mortality, incidence of bleeding, and cardiac arrhythmias.

Participants’ convenience and satisfaction with the treatment are assessed using a questionnaire at 90 days.

The study is estimated to end by February 27, 2026. Participants’ data will contribute to understanding the effectiveness and safety of anticoagulant therapy in preventing complications after CABG surgery.